References
- 1. Sagatys EM, Zhang L. Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. Cancer Control 2012;19(1):18-25.
- 2. Chiorazzi N. Implications of new prognostic markers in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2012;2012:76-87.
- 3. Obermann EC, Went P, Tzankov A, et al. Cell cycle phase distribution analysis in chronic lymphocytic leukaemia: a significant number of cells reside in early G1-phase. J Clin Pathol 2007;60(7):794-7.
- 4. Thomadaki H, Scorilas A. BCL2 family of apoptosis-related genes: functions and clinical implications in cancer. Crit Rev Clin Lab Sci 2006;43(1):1-67.
- 5. Garrido C, Galluzzi L, Brunet M, et al. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 2006;13(9):1423-33.
- 6. Leibowitz B, Yu J. Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 2010;9(6):417-22.
- 7. Burlacu A. Regulation of apoptosis by Bcl-2 family proteins. J Cell Mol Med 2003;7(3):249-57.
- 8. Tzifi F, Economopoulou C, Gourgiotis D, et al. The Role of BCL2 Family of Apoptosis Regulator Proteins in Acute and Chronic Leukemias. Adv Hematol 2012;2012:524308.
- 9. Mariano MT, Moretti L, Donelli A, et al. bcl-2 gene expression in hematopoietic cell differentiation. Blood 1992;80(3):768-75.
- 10. Meijerink JP. t(14;18), a journey to eternity. Leukemia 1997;11(12):2175-87.
- 11. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993;82(6):1820-8.
- 12. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99(24):15524-9.
- 13. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102(39):13944-9.
- 14. Nuckel H, Frey UH, Bau M, et al. Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 2007;109(1):290-7.
- 15. Majid A, Tsoulakis O, Walewska R, et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood 2008;111(2):874-7.
- 16. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343(26):1910-6.
- 17. Pettitt AR, Sherrington PD, Stewart G, et al. p53 dys-function in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 2001;98(3):814-22.
- 18. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009;15(3):995-1004.
- 19. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18(8):1391-400.
- 20. Ringshausen I, Schneller F, Bogner C, et al. Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in BCLL: association with protein kinase Cdelta. Blood 2002;100(10):3741-8.
- 21. Barragan M, Bellosillo B, Campas C, et al. Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood 2002;99(8):2969-76.
- 22. Hewamana S, Alghazal S, Lin TT, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111(9):4681-9.
- 23. Panayiotidis P, Ganeshaguru K, Foroni L, Hoffbrand AV. Expression and function of the FAS antigen in B chronic lymphocytic leukemia and hairy cell leukemia. Leukemia 1995;9(7):1227-32.
- 24. Osorio LM, Aguilar-Santelises M, De Santiago A, et al. Increased serum levels of soluble Fas in progressive BCLL. Eur J Haematol 2001;66(5):342-6.
- 25. Pepper C, Lin TT, Pratt G, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112(9):3807-17.
- 26. Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 2009;113(18):4403-13.
- 27. Karan-Djurasevic T, Palibrk V, Zukic B, et al. Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. Med Oncol 2013;30(1):405.
- 28. Robertson LE, Plunkett W, McConnell K, Keating MJ, McDonnell TJ. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996;10(3):456-9.
- 29. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. Journal of Clinical Oncology 1999;17:399-408.
- 30. Faderl S, Keating MJ, Do KA, et al. Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). Leukemia 2002;16(6):1045-52.
- 31. Aviram A, Rabizadeh E, Zimra Y, et al. Expression of bcl-2 and bax in cells isolated from B-chronic lymphocytic leukemia patients at different stages of the disease. Eur J Haematol 2000;64(2):80-4.
- 32. Saxena A, Viswanathan S, Moshynska O, et al. Mcl-1 and Bcl-2/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol 2004;75(1):22-33.
- 33. Packham G, Stevenson FK. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 2005;114(4):441-9.
- 34. Placzek WJ, Wei J, Kitada S, et al. A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy. Cell Death Dis 2010;1:e40.
- 35. Rogalinska M, Franiak-Pietryga I, Blonski JZ, et al. Toward personalized therapy for chronic lymphocytic leukemia: DSC and cDNA microarray assessment of two cases. Cancer Biol Ther 2013;14(1):6-12.